Breaking News

ANI, IDT Ink U.S. Generic Commercialization Pact

ANI expands marketed generic product portfolio

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ANI Pharmaceuticals, Inc. has entered an agreement with IDT Australia, Ltd. to commercialize as many as 18 marketed U.S. generic drug products. ANI paid $1.0 million for exclusive rights to the North American market and will share in a percentage of profits upon commercialization. The total current annual U.S. market for these products is $538 million according to IMS Health.    Arthur S. Przybyl, president and chief executive officer of ANI Pharmaceuticals, stated, “This partnership rep...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters